Español 
English 
PREDI-LYNCH
PREDI-LYNCH
Validated non-invasive liquid biopsy tests for cancer prediction in Lynch syndrome
Who are we?
Coordinated by Oslo University Hospital, the project brings together 28 partners from 16 countries, including leading academic institutions, biotechnology SMEs, healthcare organisations and patient associations.
Over six years (2025–2031), the consortium will develop and validate liquid biopsy-based screening methods to create tools for the early detection of hereditary cancer.
What is our objective?
The project aims to improve risk assessment tools that combine genetic markers, family history and lifestyle factors.
This holistic approach enables healthcare providers to offer screening and prevention strategies tailored to each patient, ultimately reducing cancer incidence and improving long-term outcomes.
The University of Granada (UGR), through the Youngner Chair in Empirical Bioethics (CYBE), is responsible for the ethical and legal management of the project, identifying regulatory and ethical requirements from the outset.
While coordinating the Independent Ethical Advisory Board (IEAB), it will provide general guidance and ongoing support to the clinical team.
What does the project involve?
The PREDI-LYNCH project is dedicated to advancing the early detection and personalised prevention of Lynch syndrome, an inherited condition that predisposes individuals to colorectal, endometrial and several other types of cancer.
PREDI-LYNCH aims to validate new non-invasive strategies for the early detection of tumours and precancerous lesions through an accessible at-home test to improve early diagnosis and outcomes.
How do we do it?
A clinical trial will evaluate tools based on liquid biopsy testing and multi-omics analyses of plasma, urine, stool and gynaecological samples, validated for cancer prediction in Lynch syndrome.
The project includes 2,000 carriers across 13 hospitals, where eight liquid biopsy technologies will be tested. The response to these technologies will be evaluated by a multidisciplinary team.
Ethical oversight and the active participation of patients and public-sector professionals will ensure transparency and inclusion.
Impact
The results of PREDI-LYNCH will contribute to the European Commission’s priorities, in line with the Europe’s Beating Cancer Plan.
The project aims to identify new biomarkers and non-invasive technologies for the early detection of hereditary cancer and risk stratification in Lynch syndrome carriers.
Given that Lynch syndrome affects 1 in 300 people and carries a lifetime risk of colorectal cancer of up to 80%, innovation in accurate and less invasive diagnostic methods is essential.
With more than 500,000 new colorectal cancer cases each year in Europe and an estimated cost of €19 billion, PREDI-LYNCH aims to reduce this health and economic burden.
Funding
Granting authority: European Health and Digital Executive Agency (HaDEA).
Programme: Horizon Europe.
Funded by the European Union: HORIZON-MISS-2024-CANCER-01-03: Accessible and affordable tests to advance early detection of heritable cancers in European regions (IA).
This project has received funding from the European Union’s Horizon Europe research and innovation programme under the Cancer Mission, Grant Agreement No. 10121916.
